The Glial and Mesenchymal Elements of Gliosarcomas Share Similar Genetic Alterations by Boerman, R.H. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/23093
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Journal of N europathology and  Experim ental Neurology
Copyright ^  19% by the American Association of Neuropathologists
Vol. 55, No. 9 
September, 1996 
pp. 9 7 3 -9 8 1
The Glial and Mesenchymal Elements of Gliosarcomas
Share Similar Genetic Alterations
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Abstract, The cellular origin ol the sarcomatous component of gliosarcomas is controversial. It is not clear if the sarcoma 
arises in transition Irom the glial cells that comprise the gliomatous component or independently arises from non-neoplastic 
mesenchymal cells oí the tumor stroma. Using comparative genomic hybridization (CGH) along with cytogenetic analysis, 
fluorescence in situ hybridization (FISH) analysis, and polymerase chain reaction (PCR) analysis of microsatellite allelic 
imbalance, we have evaluated the genetic alterations in the gliomatous and sarcomatous components of five gliosarcomas. 
The glial element was grade 4 librillary astrocytoma (glioblastoma multiforme) in all five tumors. The sarcoma elements were 
fibroblastic without osseous* chondroid, or angiosareomatous differentiation. Gain of chromosome 7, loss of chromosome 10, 
deletions of the chromosome 9 p-arm. and alterations of chromosome 3 were frequently observed, demonstrating that glios- 
arcomas can be genetically classified as belonging to the spectrum of glioblastomas. Furthermore, the sarcomatous and 
gliomatous portions of each gliosareoma investigated were similar with respect to both the presence and absence of specific 
genetic alterations. This observation supports the hypothesis that the sarcomatous component of a gliosareoma either arises 
from the same common precursor cell as the gliomatous portion, or it arises from the gliomatous portion itself.
Key Words: Comparative genomic hybridization (CGH); Genetic alterations; Gliosareoma,
INTRODUCTION or from a com m on precursor cell (15, 21). The ex istence
The gliosareom a, also termed "Feigin tum or/’ is a di- o f  connective tissue within gliosarcomas w ould then con-
morphic neoplasm  containing both gliomatous and sar- stitute an example ot fibioplastic metaplasia. N eop lastic
com atous elem ents (1 -5 ) .  Its incidence has been various- astiocy tes can foim  collagen, and som e investigators
ly estimated as 2 to 8% o f  malignant gliom as (6 -8 ) . The have proposed to broaden the concept o f  gliosareom a to
glial com ponent is usually a grade 4 fibrillary astrocy- include all collagen-pioducing astrocytomas (14 , 1 5 ,2 2 ) .
toma or glioblastom a multiforme (G BM ), although sar­
com atous elem ents have been described in association
The existence o f  gliosarcomas as a separate entity has 
even been questioned, and some investigators have in-
with oligodendrogliom a (9), subependym om a (10), neu- eluded them in the specttum o í G B M  (15, 21).
roblastoma ( II ) ,  and even  metastatic carcinoma (12). The cellular origin o f  the sarcomatous com ponent o f
D espite numerous m orphological and histochemical gliosarcomas can be evaluated using genetic techniques.
studies, the cellular origin o f  the sarcomatous elements If the sarComa and Slioma arise from a com m on precur- 
is controversial (1 3 -1 5 ) .  The sarcoma usually has histo- sor- then both components should exhibit similar genetic
logic features o f  malignant fibrous histiocytoma (16). alterations. However, if the sarcoma is induced by the
However, other types o f  sarcoma have also been de- G B M - then different Senetic chanSes should be observed  
scribed as having osteocartilagenous or even m yxom a- in the tw0 elements because each com ponent will have  
tous features (10, 13, 17-19). Thus, the cell underlying derived from a different precursor c e l l .J h e  technique of
the developm ent o f  the sarcoma com ponent appears to 
have the potential to differentiate toward a variety o f  
m esenchym al cell types (13).  Even though the sarcoma
comparative genom ic hybridization (CGH) is a powerful 
new genetic tool, one especially suited for such experi­
ments since it provides an overview  o f  D N A  sequence
has been hypothesized to arise as an independent tumor CCW  number chan8 es without the necessity o f  cell culture
(13, 14, 20) induced in the stromal m esenchym e by the (23). In this study, we have applied CGH and other com
glial tumor, the sarcoma could arise from the gliom a itself P^mentary analyses to exam ine the genetic alterations in
the glial and mesenchymal components ot g liosarcom as.
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MATERIALS AND METHODS 
Tumor Samples
The tumors for this study were selected from a series of 30 
gliosarcomas present in the Mayo Clinic Tissue Registry  and 
brain tumor bank, as well as from the consultation file of BW S. 
The primary criterion for case selection was the availability of 
frozen tumor, this being necessary to validate the CG H  results 
obtained with DNA extracted from paraffin-embedded tissue.
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TABLE 1
Clinical Findings on Five Patients with G liosareom a
Case
Survival 
(years from 
diagnosis/years
no. Age/Sex Diagnosis Location Surgery Radiotherapy Chemotherapy from surgery)
1 60/M Gliosareoma R-temporal GTR 50 Gy BCNU/Temozolam ide Dead (2.50/2.25)
2 67/M Gliosarcomn R-occipital GTR 64.8 Gy B C N U /M O P Dead (1.70/1.50)
3 41/F Oligodendroglioma R-frontal GTR Dead (3,75/3.75)
Recurrent gliosareoma R-frontal STR 58 Gy Dead (3.75/1.75)
Recurrent gliosareoma R-frontal STR Dead (3.75/0.50)
4 67/M Gliosareoma R-frontal GTR 50 Gy B C N U Dead (0.60/0.60)
5 33/M Gliosareoma L-frontal GTR 60 Gy Alive (2.00/2.00)
G TR =  Gross Total Resection; STR = Stereotactic Resection; Gy = Gray,
Essential clinicopathological data regarding the 5 patients 
whose tumors were studied are shown in Table 1. The frozen 
tum or samples were split into adjacent fragments, and one Di­
more of the fragments were used for CGH analysis. The frozen 
tum or fragments adjacent to those used for CGH were sectioned 
and histologically evaluated. The adjacent fragments o f cases
1, 4, and 5 contained both glioma and sarcoma, and those of 
case 3 contained only sarcoma. An adjacent fragment was not 
available for case 2. The samples from patient 3 were derived 
from  the third operation.
Paraffin-embedded specimens were routinely fixed in 4% 
neutral buffered formalin for 12 hours to 3 davs. In all cases 
the diagnosis o f  gliosareoma was confirmed by a neuropathol­
ogist (BWS) using histochemical stains, e.g. hematoxylin/eosin 
(H&E), Gomori reticulin, phosphotungstic acid and hematoxy­
lin (PTAH), and by immunocytochemical preparations (glial fi­
brillary acidic protein and S-100 protein). The tumors were 
classified in accordance with the W HO classification (5) and 
the criteria of M eis et al (16). The tumors were typical examples 
of gliosareoma. The glial element was grade 4 fibrillary astro­
cytom a (glioblastoma multiforme) in all 5 tumors. The sarco­
matous elements were fibroblastic in nature. No osseous, chon­
droid, or angiosarcomatous differentiation was noted, Paraffin 
blocks were selected which contained clearly distinct regions 
o f glioma and sarcoma, each region measuring approximately
0,5 cm 2 unassociated with necrosis. Greater than 70% neoplas­
tic tissue was present within these regions, the remainder being 
stromal or reactive tissue.
DNA Extraction
Reference genomic DNA from peripheral blood leukocytes 
o f a healthy male donor as well as frozen tumor DNAs were 
isolated according to standard procedures (24).
D N A  was derived from paraffin-embedded tissues as follows: 
Sixty-four 4\im  sections were cut from the paraffin blocks. The 
first and last two sections were stained with H & E and reticulin 
for the purpose o f identifying sarcoma, glioma, and normal tis­
sue elements. O f  the intervening consecutive sections, 25 were 
placed on glass slides for in situ hybridization and 35 on cel­
lulose acetate sheets (PP2200 from 3M; cut to the size of glass 
slides and precleaned with 100% ethanol). The acetate slides 
were deparaffinized (2 X 10 minutes in Histoclear followed by
2 X 10 minutes in 100% ethanol). Specific areas of interest
were cut out o f  the acetate slides with a scalpel and placed in 
microfuge tubes. Incubation with proteinase K (Sigma, St Lou­
is, MO) was carried out for 3 days as described elsewhere (25, 
26). DNA was extracted with the IsoQuick kit (O R C A  Re­
search, Bothell, WA). The DNA solution was added to a 
M icrocon-100 m icroconcentrator (Amicon Inc, Beverly, MA) 
and eluted by centrifugation (27). DNA size was determ ined by 
gel electrophoresis (nondenaturing 1% agarose gels with ethid- 
ium bromide staining), D N A  concentration was measured with­
in the gel by tluorometry (MTI camera C C D 72 and NIH Image
1.57 software) and compared to a standard o f  known concen­
tration which was electrophoresed simultaneously,
Labeling of DNA
Nick translation was performed as described elsewhere (23, 
26) using the Gibco kit (Gibco BRL, Gaithersburg, MD) and a 
modified l()x dN TP mix (0.4 mM dATP, dGTP, and dCTP; 0.8 
mM dTTP; 500 mM TrisHCl [pH -  7.5]; 50 mM  MgCU; 100 
(xg/mL BSA; and 100 mM 2-mercaptoethanol). The nick trans­
lation reaction time was 45 minutes; then the reactions were 
terminated by the addition of stop buffer from the Gibco kit. 
Direct (2 nmol F luoroG reen-dU T P  and F lu o ro R ed -d U T P  
[Amersham, Arlington Heights, IL]) and indirect labels (2 nmol 
biotin-16-dUTP and 2 nmol digoxigenin-11-dUTP [Boehringer 
Mannheim, Indianapolis, IN]) were compared for labeling ef­
ficiency, signal intensity, and variation on control specimens 
(see below). Indirect labels were used in all subsequent exper­
iments; the tumor D N A  was labeled with biotin and the refer­
ence D N A  with digoxigenin. After nick translation, the sizes of 
the tester (tumor) and the reference DNA probes were deter­
mined by agarose gel electrophoresis. These sizes ranged be­
tween 200 to 3000 bp for all samples. Also, D N A  concentration 
was measured by fluorometry and the amounts o f D N A  were 
adjusted so that the concentration of the tumor D N A  probe 
equaled the concentration o f the reference D N A  probe.
CGH
To prepare the probe solution, 300 ng o f both the labeled 
tester and reference DNA were precipitated together with 30 
mg of Cot-1 D N A  (Gibco) according to a standard procedure 
(24) and the pellet was redissolved in hybridization mixture 
(50% formamide, 2XSSC, 10% dextran sulfate, pH =  7.2). The
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probe solution was denatured for 5 minutes at 80°C, quenched 
on ice, and allowed to preanneal at 37°C for 2 hours before 
application to the slides.
Metaphase chromosomes were cultured from PH A-stimulated 
peripheral blood lymphocytes of a normal healthy male donor 
according to standard cytogenetic procedures. Dropping fixed 
metaphase suspensions onto glass slides using routine cytoge­
netic techniques produced preparations with highly variable 
chrom osom e m orphology and multiple chromosomal overlaps. 
These preparations gave inconsistent and incomplete CGH re­
sults. Dropping fixed metaphase suspensions onto slides in a 
controlled environm ent cham ber (Thermatron Industries, Hol­
land, MI) at a relative humidity o f  50% and a temperature of 
25 °C resulted in preparations with very consistent chromosomal 
morphology and optimal chrom osom al spreading (28). CG H  re­
sults were consistent with these preparations. Slides containing 
metaphase spreads prepared by this method were incubated 
with RN ase A (Boehringer; 100 m g/m L in 2XSSC) for 1 hour 
at 37°C, digested with pepsin (Sigma, 0.1 mg/mL in 0.01 M 
HCl) and postfixed with formaldehyde (Fisher Scientific, Pitts­
burgh, PA; 1% in PBS with 50 mM MgCL) (29). The slides 
were denatured in 70%? form am ide/2XSSC (pH =  7.2) at 80°C 
for 2 minutes in a hybridization oven, quenched in 70% ethanol 
at — 20°C, and dehydrated in graded ethanols. Hybridization 
was carried out under sealed coverslips for 3 days at 37°C in a 
moist container.
After hybridization, the slides were washed 3 X 5  minutes 
in 50%i form am ide/2X SSC (pH = 7.2) at 37°C, 3 X 5 minutes 
in 0 .1X SSC (pH -  7.2) at 60°C and once in 4XSSC at room 
temperature. For immunocytochemical staining, the slides were 
preincubated with 0.5% dry milk powder in 4XSSC for 30 min­
utes at 37°C in a moist container. The DNA sequences were 
visualized by incubation with streptavidin-FITC (Vector Labo­
ratories, Inc, Burlingame, CA) and anti-digoxigenin-Rhodamine 
(Boehringer) (both diluted 100-fold in 0.5% dry milk powder 
in 4X SSC ) for 60 minutes at 37°C in a moist container and 
washed 3 X 5  minutes with 4XSSC/0.05%  Tween. Chromo­
some preparations were dehydrated and counterstained with 4 '- 
6-diam idino-2-phenylindoledihydrochloride (DAPI, Serva, Ger­
many).
Image Analysis
The images were captured with a Zeiss Axiophot fluores­
cence microscope (Carl Zeiss Inc, Thorn wood, New York) 
equipped with a 100 Neo-Fluar objective, a computer-controlled 
filter wheel, and a cooled CCD  camera (Photometries, Tucson, 
AZ). Analysis was carried out on a PowerM ac computer loaded 
with Smartcapture IPLab Extensions software (VYSIS, Down­
ers Grove, IL and Digital Scientific, Cambridge, United King­
dom). The image analysis procedure was performed using pre­
viously described methods (23, 30) with minor modifications.
with seizure disorders, and from short-term cell cultures derived 
from high grade astrocytomas. The average fluorescence ratio 
(FR) for CGH with normal D N A  as tester was 1.0 (range 0.9 
to 1.1) with a standard deviation of 0.1. T he X -chrom osom e 
FR in CGH experiments using normal male against normal fe­
male DNA samples was 0.4 (SD = 0 . 1). Experiments with tes­
ter DNAs extracted from paraffin-embedded non-neoplastic  
brain tissue yielded similar results. Aberrations present in the 
cultured tumors were detected as FRs above 1.25 for numerical 
or regional chromosomal gain and below 0.75 for numerical or 
regional chromosomal loss. The ratios correlated to the know n 
aberrant copy number obtained by routine cytogenetic analysis 
o f  the cultured tumors (data not shown). However, an exact 
linear relationship (31) between copy number and ratio could 
not be established because the short-term cultures were not 
monoclonal. Therefore, based on these experim ents and the 
published requirements for quantitative analysis o f  C G H  (32), 
FR thresholds of 0.75 and 1.25 were chosen to distinguish n u ­
merical and regional chromosomal loss and gain, respectively. 
A regional amplification was defined as an FR >  2.0, Finally, 
each gliosareoma CGH experiment was perform ed sim ulta­
neously with a control hybridization using normal D N A  as a 
tester to measure the normal autosome and X  chrom osom e FR.
Validation by Reverse CGH, Fluorescence In Situ 
Hybridization (FISH) and Polymerase Chain 
Reaction (PCR) Analysis of 
Microsatellite Alleles
Reverse CGH (23) was carried out on all frozen specimens 
and a subset of the paraffin-embedded specimens to indepen­
dently ascertain the alterations found in the initial experiments. 
This time the tester (tumor) DNA was detected w ith  a red fluo- 
rophore, and the reference DNA was detected with a green fiuo- 
rophore.
Fluorescence in situ hybridization (FISH) was perform ed on 
paraffin-em bedded tissue sections using S p ec tru m O ran g e-  
labeled chromosome enumeration probes (C E P ^5, Vysis, Inc, 
Downers Grove, IL) for chromosomes 7, 10, and 17 as de­
scribed elsewhere (33). Chromosomes 7 and 10 were chosen 
because gains of chromosome 7 and losses o f  chrom osom e 10 
were the most com m on numerical abnormalities observed by 
CGH. They also constitute the most com m on alterations in 
GBM  (34-38); furthermore, monosomy 10 has been described 
in gliosarcomas (39). Chromosome 17 was chosen because it 
represented a chromosome without numerical loss in the C G H  
experiments. However, chromosome 17 is o f  particular interest 
because its centromeres are usually paired in normal brain cells, 
and the loss of this pairing may have biological significance in 
gliomas (33, 40). The CEP signals were evaluated using a  Zeiss 
Axioplan fluorescent microscope equipped for FITC, TR ITC , 
and DAPI fluorescence. The number o f  signals w ithin 300 nu-
In order to obtain average CG H  fluorescence ratio curves, 5 to c]e¡ ^  enumerated by two different observers using previ-
10 metaphase spreads were analyzed from each tumor.
Control Experiments and Abnormal Fluorescence 
Ratio Thresholds
We perform ed a num ber o f  control CG H  experiments using 
DNAs derived from leukocytes o f  healthy male and female do­
nors, from non-neoplastic brain tissue resected from patients
ously described criteria (41, 42).
Paired blood and tumor samples for three patients (cases I,
2, and 3) were available for PCR analysis o f  microsatellite al­
lele imbalance, which was performed as described previously 
(43). The markers evaluated were selected because either they 
mapped to regions showing loss or gain in the C G H  experi­
ments, or they mapped to regions known to be involved in
J  Neuropathol Exp Neurol, Voi 55. September, 19(J6
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GBM . T he films were evaluated by visual inspection; in cases 
o f equivocal results, neighboring markers were evaluated. The 
markers used were: D IS  199, D3S1284, D3S1309, D3S1268, 
D 3S 1306 , D 6S273, D 6S263, D7S484, D 7S486, D7S507, 
D 7S522, D 8S273, D9S126, D9S171, D 9S157, D 9S163, 
D10S226, D10S219, D11S987, D17S796, D17S786, D22S421, 
and D22S281 (all obtained from Research Genetics, Huntsville, 
AL).
RESULTS 
CGH
CGH was performed using both DNA derived from 
frozen tumor tissue and DNA isolated from microdis-
were generally successful. However, the yield of high- 
molecular DNA was low and in most instances no more 
than two CGH experiments could be performed on each 
component. An insufficient amount of glioma tissue from 
case 4 was available for analysis and the quality of DNA 
from case 3 was poor and did not give meaningful CGH 
measurements. The latter observation was surprising be­
cause the amount of DNA was adequate, the average 
DNA fragment length did not significantly differ from 
other DNA samples, and necrosis of the tissue was lim­
ited. The most likely explanation for this inconsistency 
would be that lengthy formalin fixation chemically dam­
aged the DNA and/or the tissue underwent autolysis (see
sected sarcomatous and gliomatous components present Dubeau et al, reference 25). This would be consistent 
within paraffin-embedded tumor specimens. All results with the dim FISH signals observed on sections taken 
were rigorously controlled in repeated standard and re- from the same block (see below).
verse CGH experiments as described in Materials and The tumor components of case 5 were apparently nor-
Methods. Figure 1 illustrates typical CGH results from mal. Because normal genetic studies of GBM are rather
the frozen and paraffin-embedded tissue of case 1. The unusual, standard and reverse CGH analysis o f these tu-
frozen tumor of case 1 showed gains of chromosome 7 mors was repeated a total of 5 times without any FR
and of the long arm of chromosome 3. Losses of the short variation ever exceeding an abnormal threshold criteria.
arm of chromosome 9, the long arm of chromosome 11, A comparison of CGH results shows that all numerical
and both arms of chromosome 10 were also detected, and most regional chromosomal abnormalities present in 
Evidence of loss of the short arm of chromosome 18 was frozen tissue were also detected in paraffin-embedded tis- 
consistently observed in several experiments but did not 
exceed the abnormal FR threshold criteria. The results 
from the paraffin-embedded regions showed gains of 
chromosome 7 and losses of chromosome 10 as well as
the short arms of chromosomes 9 and 18 in both glioma
sue (see Table 2 and Fig, 1), Table 2 and Figure I also 
demonstrate that sarcomatous and gliomatous portions 
from all tumors were similar with respect to both the 
presence (case 1, 2, and 4) and absence (case 5) of CGH 
alterations. There were some minor differences between
and sarcoma. Loss of the long arm of chromosome 11 the components including loss of 1 lq in the sarcoma of
was detected only in the sarcomatous element. case U loss of chromosome 3 in the sarcoma of case 2,
Table 2 summarizes the alterations detected by CGH and losses of 9p and 2 Ip in the glioma of case 2.
for both frozen and paraffin-embedded tumor specimens. 
As described above for case 1, a number of experiments 
resulted in either no detection of alterations in one of 
multiple CGH experiments or consistent detection of a 
number of alterations that did not exceed the abnormal 
FR threshold criteria. These regions have been included 
in Table 2 and placed in parenthesis because they may
Validation
CGH results were compared with routine cytogenetic 
data, PCR analyses of microsatellite allele imbalance and 
FISH studies. The results of these experiments are sum­
marized in Table 2.
The cytogenetic analysis showed complex clonal kar-
represent important alterations in gliosarcomas. In addi- yotypes in cases I and 2 and a complex nonclonal karyo-
tion, although the p-arms of chromosomes 1 and 16 may type in case 3. For case 1, the numerical chromosomal
give rise to false CGH interpretation of deletion (23), abnormalities and the loss of 9p detected by CGH match
they are also included in Table 2 because these regions the cytogenetic results. For case 2, the numerical altera-
were apparently gained in some tumors. tions and the deletions of the long arm of chromosome
The most frequent reproducible CGH alterations in the 18 detected by CGH also correlate with the cytogenetic
frozen specimens were: gain of some or all of chromo- observations. However, for case 3, the CGH alterations
some 7 (4 cases), loss of chromosome 10 (2 cases), and were not observed in the single abnormal cell that was
loss of 9p (2 cases). These results were also present in available for karyotype analysis.
the paraffin-embedded tumor tissue for two cases (cases
1 and 2). Gains of the chromosomes lp-arm and 3q-arm 
were detected in two frozen tumors each. Alterations of
The results of PCR analysis of microsatellite allelic im­
balance often matched the CGH data. For example, most 
regional or chromosomal losses detected by CGH in fro-
lq, 6p, 7p, 8q, lip , llq , and 16p were each detected zen tumor specimens were also detected as regional im-
only once in the frozen tumors studied. balances of microsatellite alleles. The sole exception for
The CGH experiments performed using the microdis- this was case 1 in which CGH detected the loss of llq  
sected DNA from paraffin-embedded tumor specimens but microsatellite analysis did not. However, the regional
J Neuropathol Exp Neurol, Voi 55, September, 1996
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Fig. 1. An overview  of the CG H  alterations detected in frozen specimens and paraffin blocks of case 1. C olum n I: C G H  
results on a frozen specimen* Columns 2 and 3: CG H  results on microdissected gliomatous and sarcomatous com ponents. T h e  
Y-axis for each graph displays fluorescence ratio (FR) for selected chromosomes. The mean FR, measured on 5 to 10 metaphases, 
is indicated by the red line. The standard deviation o f the FR is indicated by the blue and green lines. The X-axis has been 
normalized to the relative length o f  the chromosome (as a percentage of the total haploid autosome length) with the p-arm  to the 
left. The dashed horizontal lines indicate FR thresholds of 0.75 and 1.25 used to distinguish numerical and regional chrom osom al 
loss and gain, respectively.
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TABLE 2
Sum m ary o f  Genetic Studies on Frozen Tum or Specimens and M icrodissected Paraffin-embedded Gliomatous and Sarcomatous Com ponents From  Five
Gliosarcomas
C G H  Analysis
PCR analysis o f  
microsatellite alleles
Case no./Tissue type Gain Loss FISH  analysis Karyotype* Im balance N o imbalance
1) Frozen tum or (glioma and sarcoma) 3q, 7 9p, 10, l l q , 44, XY, + 7 , - 1 0 ,  - 1 1 7p, 7q, 9p, 10p, Ip, 3p, 3q, 6p,
(18p)** X 2, add( 1 )(q42), 
add(9)(pl3), + 3 -  
5mar[cp2]/45, X, 
—Y[4]/44, X X [4]
lOq 8q, l l q ,  17p,
22q
Paraffin-embedded regions:
G liom a 7 9p, 10, 18p + 7 , - 1 0 ,  split 17 N A N D N D
Sarcoma 7 9p, Ï0, l l q ,  18p + 7 , - 1 0 ,  split 17 N A N D ND
2) Frozen tum or (glioma and/or sarcoma) lp ,  Iq, 7 9p, 10, (18q) N D 47, XY, + 7  X 2, - 1 0 , 9p, 10p, lOq lp , 3q, 7p, 7q,
- 1 1 ,  t( 1 ;20)(p22;p 13),
t(3;15)(q21;q22),
der( 18)t( 1 ; 18)(q 11 ;q21 ),
-}-mar[30]
8q, l l q ,  17p, 
22q
Paraffin-embedded regions:
G liom a l q , 7  9p, 10, 18q ,(21p) + 7 ,  - 1 0 ,  split 17 N A N D ND
Sarcom a 7 3, 10, 18q + 7 , - 1 0 ,  split 17 N A N D ND
3) Frozen tum or (sarcoma) Ip, 3q, 6p, (3p) N D 46, XX, add(l)(q23), 3p ip , 3q, 7p, 7q,
7p, 8q del(4)(pl4),
del(7)(q32),
de l(9 )(p l3),
del(10)(p l3),
del(13)(q l4),
add(16)(q22)[l]
8q, 10p, 10q, 
l l q ,  17p
Paraffin-embedded regions:
Glioma not interpretable -f 7, N10, split 17 NA ND ND
Sarcom a not interpretable + 7 ,N 1 0 ,  split 17 N A N D ND
4) Frozen tum or (glioma and sarcoma) 7, ( l i p ,  I6p) ND N D N D ND
Paraffin-embedded regions:
G liom a N D  N D + 7 , - 1 0 ,  split 17 N A N D N D
Sarcom a 7 + 7 , - 1 0 ,  split 17 NA N D N D
5) Frozen tum or (glioma and sarcoma) N D N D N D N D
Paraffin-embedded regions:
G liom a + 7 , - 1 0 ,  split 17 N A N D N D
Sarcom a + 7 , - 1 0 ,  split 17 N A N D N D
* Cytogenetic studies were perform ed on a portion o f  the tissue prior to being frozen as previously described (Jenkins et al, 1989).
** C G H  alterations in parentheses were either not detected in one o f  several repetitions, or w ere consistently detected but d id  not exceed the  abnormal FR 
threshold criteria.
*** ND = Not Done; NA =  Not applicable; —  =  No apparent anomalies; N 10 =  Apparently normal chrom osom e 10 centromere FISH  counts.
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or chromosomal gains detected by CGH were rarely de- to the inaccuracy of current standard DNA concentration
tected by the microsatellite markers. This observation was measurement procedures (47, 48) and the large differ-
expected, since a decrease in microsatellite allele intensity enees in sample quality, especially for tumor DNAs.
is more conspicuous than an increase. Nevertheless, the Thus, after nick translation, we measured the DNA probe
overall concordance ot PCR and CGH analysis was 70% concentrations using fluorometry of gel-electrophoresed
(with a concordance of 96% for losses only) providing DNA. Then we adjusted the amounts of DNA to attain
further proof for the validity of the CGH procedure. equal concentrations of tumor and reference DNA for
Similarly, FISH analysis of paraffin sections were gen- reliable CGH results. Second, visualization and accurate
erally concordant with the CGH results tor all chromo- measurement of CGH data is often impeded by the poor
somes evaluated. For example, chromosome 7 was appai- quality of the normal metaphase preparations used as the
ently gained and chromosome 10 was apparently lost in hybridization substrate. We observed that the use of an
cases 1 and 2 by both CGH and FISH. For case 3, neither environmentally controlled chamber to prepare the slides
FISH nor CGH analysis revealed any apparent chromo- ensures that the normal metaphases are optimally spread
some 10 or 17 anomaly. In addition, FISH detected a gain and of excellent morphology (28). This procedure greatly
of the chromosome 7 centromere in the paraffin sections improves the selection of metaphases and simplifies CGH
of both components and CGH detected a gain of the chro- analysis.
mosome 7 p-arm in the frozen sarcomatous tissue. In some The CGH method is a reliable and valid tool for the
instances, the FISH and CGH analyses were discordant, evaluation of genetic alterations in frozen and paraffin-
Loss of chromosome 10 and gain of chromosome 7 were embedded tumor specimens. The main advantage of CGH
detected by FISH in cases 4 and 5. However, only the gain is that most major chromosomal abnormalities present
of chromosome 7 was detected by CGH in case 4. Normal within a tumor can be detected in a single experiment,
copy numbers lor chromosome 17 were found in all sam- This makes CGH attractive to perform compared to the
pies; but in contrast to normal tissue, the homologues were laborious enumeration of a wide range of possible chro­
no longer somatically paired in tumor cells. Overall, aeon 
cordance of 70% was found between FISH and CGH.
DISCUSSION
mosomal anomalies by FISH. CGH can potentially select 
the chromosomal anomalies which would be appropriate 
to study by FISH. Moreover, CGH is almost always pos­
sible if frozen tissue is used for DNA isolation. However, 
The nature of gliosareoma has long been debated and CGH does have some disadvantages. First, CGH will only
has been the subject of numerous studies (1-22). There­
fore, fundamental data regarding its molecular biology,
detect clonal anomalies if they are present in more than 
50% of the cells from which the DNA was derived. This 
particularly as compared to that of GBM, must be col- limit is defined by the 0.75 and 1,25 thresholds used in
lected. We used CGH to evaluate the presence and ab­
sence of genetic alterations in gliosarcomas. We devoted
CGH (23, 31, 32). This may be the reason why CGH was 
unable to detect the loss of chromosome 10 in cases 4 and 
considerable effort to optimize and validate our CGH ex- 5 and the gain of chromosome 7 in case 5 that were de- 
periments. The CGH procedure which we finally adopted tected by FISH. Alternatively, this discrepancy may be 
for this study was reliable because the results were gen- attributed to the loss (or gain) of the centromeric region 
erally concordant with cytogenetic data, FISH analysis, without alteration of the rest of the chromosome. This phe- 
and PCR analysis. Other groups have also confirmed the nomenon is possible but is thought to be unusual. Another 
general validity of CGH (23, 44-46). In addition, we explanation might be sampling bias, but since adjacent tis- 
liave demonstrated that CGH analysis can be successfully sue sections were used for FISH and CGH, this is also 
performed on DNA derived from paraffin-embedded unlikely. Second, the abnormalities detected by CGH did 
specimens. These CGH analyses were generally concor- not differ much from those detected by routine cytogenetic 
dant with CGH studies of matched frozen tissue speci- analysis. Therefore, because cytogenetics analysis can de­
mens. However, three cases showed a small number of tect balanced translocations and often small deletions, it is 
regional gains in the frozen specimens but not in the still useful for detecting genetic anomalies. Third, although 
paraffin-embedded specimens (e.g. gains of lp, 3q, l ip,  CGH is an elegant procedure, it is not easy to perform 
and 16p). Given the overall concordance of the frozen and requires rather sophisticatec and expensive micro- 
and paraffin-embedded results, this likely reflects the dif- scopic equipment and image am lysis software. Finally, 
ficulty of performing CGH experiments on a limited successful CGH requires meticul )us attention to detail,
amount of paraffin-embedded tissue. Similar results have 
been described by Isola et al (26) for other tumors.
whereby the procedure must be repeated in both standard 
and reverse conditions and the results should be checked
Two technical points of the CGH procedure must be using other methods.
discussed. First, accurate quantitation of the concentra­
tions of the tumor and reference DNAs is critical for re­
liable CGH results. This is not always easy to attain, due their separate glial and mesenchymal elements. Our CGH
This is the first study to provide an overview of the 
genetic alterations observed in gliosarcomas, specifically
J Neuropathol Exp Neurol, Val 55. September. 1M6
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observations are similar to those of prior CGH studies of although alterations of chromosome 3 were common in
malignant gliomas (49-51) and glioma cell lines (52) as this group of gliosarcomas and have been thought to be
well as other genetic studies of high grade gliomas (34— less common in GBM (34-36, 49—50). Importantly,
38). Gains of chromosome 7, losses of chromosome 10, gliosareoma remains an interesting biological entity for
and deletions of the chromosome 9 p-arm were common further investigation. The tumor appears to represent an
and firmly establish gliosarcomas within the spectrum of example of either a precursor cell differentiating toward
two histologically different components, or of mesenchy­
mal metaplasia of neoplastic glial cells. Further studies
malignant astrocytic tumors (36, 39).
We did not detect loss of chromosome 17 (39) or an 
imbalance of 17p microsatellite alleles in gliosarcomas. will be required to determine which of these pathways 
The absence of these anomalies is interesting because underlies the “divergent differentiation1’ of gliosarcomas. 
they are common in high grade astrocytomas and often 
occur in combination with chromosome 10 and 9p losses 
(53, 54)* The only abnormality detected was the loss of 
homologous pairing of the chromosome 17 centromeres 
in all sarcoma and glioma regions. Conversely, the nor­
mal areas from the same specimens retained homologous 
pairing (data not shown). This phenomenon may be of 
functional importance in normal brain cells (55), although 
its significance in tumors is still unclear (33,40), Perhaps 
the most interesting observation is the involvement of 
chromosome 3 in three gliosarcomas. Although the num­
ber of cases is small, this may point to an important clon­
al alteration leading to the development of this complex 
tumor. Finally, the other gains (lp, lq, 6p, 8q) and losses 
( l lq ,  18p, 18q) we observed by CGH have also been 
detected by prior CGH studies of gliomas (49-51) or 
glioma cell lines (52).
The most intriguing aspect of gliosareoma biology is 
the emergence of the sarcomatous component. Our data 
presented in Figure 1 and in Table 2 indicate that the 
genetic makeup of both components is similar and often 
identical. These observations do not support the hypoth­
esis of an independent sarcoma originating from an en­
dogenous mesenchymal stem cell, residing within tumor 
stroma. Instead, our results are consistent with the hy­
pothesis that the sarcomatous component arises by a pro­
cess of ‘‘divergent differentiation” either from the same 
common precursor cell as does the gliomatous compo­
nent or by metaplasia from the gliomatous component 
itself. It is remotely possible that the findings in this study 
simply reflect the contamination of the sarcomatous com­
ponent with glioma tissue. However, the blocks were se­
lected for the presence of clearly distinct glioma and sar­
coma elements. Moreover, our results are supported by a 
prior FISH study (39) and by the recently published find­
ing of identical mutations of the p53 gene within the 
sarcoma and glioma portions of 2 gliosarcomas (56).
In conclusion, we believe that the term gliosareoma 
describes a morphological entity and should continue to 
be used as such. The genetic alterations of both the gli­
oma and the sarcoma elements of gliosareoma are similar 
to one another and to the pattern of genetic aberrations 
observed in GBM. These observations support a common 
origin o f both elements. No single genetic alteration has 
been linked to the peculiar morphology of this tumor,
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